{"id":13681,"date":"2024-02-12T14:50:37","date_gmt":"2024-02-12T14:50:37","guid":{"rendered":"https:\/\/www.nanion.de\/?post_type=news&p=13681"},"modified":"2024-02-12T14:54:40","modified_gmt":"2024-02-12T14:54:40","slug":"external-interview-bettina-lickiss-for-biotechniques","status":"publish","type":"news","link":"https:\/\/nanion.com\/zh-hans\/news\/external-interview-bettina-lickiss-for-biotechniques\/","title":{"rendered":"External Interview-

Bettina Lickiss for BioTechniques<\/p>"},"content":{"rendered":"

\n
\n\t

In a recent interview with BioTechniques<\/a>, innoVitro<\/a> a German CRO company with core competence in a broad spectrum of cell analytics assay, discussed key insights from their collaboration with Nanion.<\/p>\n

Showcased at ELRIG 2023. the focus of the discussion was on the innovative AtlaZ platform for live-cell analytics<\/a>, utilizing electrical impedance spectroscopy with gold electrodes in a 96-well plate. This technology allows real-time analysis of diverse cellular responses, offering a high-throughput advantage across six 96-well plates simultaneously. The platform's versatility encompasses the real-time assessment of cell adhesion, proliferation, cytotoxicity, G-protein coupled receptor signaling, morphology, and barrier function.<\/p>\n

The interview focused on the notable findings from the platform's testing, highlighting the successful ratio-dependent cancer cell killing by CAR-T cells and the concentration-dependent cardiotoxic effects of doxorubicin on a cardiac phenotype cell line. The AtlaZ platform emerged as a time-efficient and powerful tool, capable of conducting multiple analyses simultaneously and catering to a broad spectrum of research projects.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>